ECOWORKS

ECOWORKS LAUNDRY DETERGENT (ALPHA FORMULATION)

Derma Consult GmbH Report

Derma
Consult
GmbH
Gesellschaft zur Prüfung von
Dermatika

DC Brunnenstraße 61 53347 Alfter Germany

Phone: +49 - (0)2222 / 9108 - 10
Fax: +49 - (0)2222 / 9108 - 40
E-mail: info@dermaconsult.com
Web: www.dermaconsult.com
Date: 15.12.2023

Expertise

Examination of the Product

"Ecoworks Laundry Alpha"

formulation code: SCLLD/GC 005/10/23

Concentration: 1,0% in water

by Human Patch Test (Cosmetic Trial)

Sponsor

Performing Laboratory
Derma Consult GmbH
Brunnenstr. 61
53347 Alfter
Germany

Study Details

Type of study.....: Determination of irritating effects to the skin with an occlusive patch test.
Study Period.....: December 2023
Study Director....: Dr. med. H. Prieur
Test subjects.....: 50 (18-66 years; sex distribution non-standardized)
30 normal healthy, 5 eczema, 1 allergy and 14 subjects with sensitive skin
Test site.....: Back
Concentration.....: 1,0% in water
Controls.....: SDS (1% in water), water

Summary Results

All participants completed the study. Under the test conditions, SDS (1% in water) caused positive reactions in 15 subjects. The negative control water showed no reactions. None of the subjects showed any reaction to the test product. On the basis of the test results and under the test conditions, the product

"Ecoworks Laundry Alpha"

is to be classified as 'harmless' as regards the possibility of skin irritation.

Signature:

Dr. med. H. Prieur
Dermatologist - Allergist

Signature:

Dr. J. Nissen
Pharmacist - M.D.R.A.

manager: Dr. Hans-Peter Nissen Dr. Jana Nissen
VAT-REG.No. DE 123369725

district court Bonn HRB 5272
Tax No. 222/5703/0374

Methodology

Introduction

The epicutaneous patch test allows us to assess the primary skin irritation potential of cosmetic-finished products and raw materials.

Description

All the work described in this expertise was conducted considering the guidelines by COLIPA (Walker A.P. et al: Test Guidelines for Assessment of Skin Compatibility of Cosmetic Finished Products in Man. Food and Chemical Toxicology 34, 1996, 651-660; COSMETICS EUROPE: Product test guidelines for the assessment of human skin compatibility 1997).
Because it was a study with humans, it was carried out taking into account the principle requirements of the Declaration of Helsinki (1964) and subsequent revisions.
Experiments were carried out on 50 volunteers (30 normal healthy subjects, 5 eczema patients, 1 allergy patients, 14 subjects with sensitive skin) between the ages of 18 to 66. Sex distribution was not standardized. The volunteers were clearly informed, verbally and in writing, regarding the nature of the study, the timetable, constraints and possible risks. They gave their written informed consent before participating in the study.
Participants could withdraw from the study at any time without giving reason. During the test period, the subjects refrained from using other substances on the test areas. Drop-outs were replaced and their data discarded.

Inclusion criteria

- informed volunteers
- age ≥ 18 years

Exclusion criteria

- pregnant or lactating women
- blemishes or marks (tattoos, sunburn) which interfere with scoring
- any skin disease that may interfere with the aim of the study

Procedure

The product was applied in a concentration as outlined above in square test-chambers (allergEAZE® clear Patch Test Chambers; SmartPractice®, Phoenix, AZ) to the backs of the panellists for a period of 48 hours. Proper adherence of the test patches was assured by the inclusion of sodium dodecyl sulphate (SDS) in one concentration (1%) as positive control. Water was used as a negative control.

The treatment sites were assessed for the presence of irritation by a trained evaluator using a 5 point visual scoring scale at 48 h (30 min after patch removal) and 72 h after patch application.

Scoring scale

Erythema	0: no E., 1: slight E., 2: significant E., 3: pronounced E., 4: strong E.
Fissure	0: no F., 1: minimal F., 2: significantly perceptible F., 3: pronounced F., 4: ulceration
Scaling	0: no Sc., 1: minimal Sc., 2: moderate Sc., 3: significant Sc., 4: closed scale crust

Results

The test results outlining the data for erythema, scaling and fissure formation on a per subject base for the test product are attached in tabulated form.

Literature

Magnus Lindberg and Mihaly Matura:
"Patch Testing" in
J. D. Johansen, P.J. Frosch, J.-P. Lepoittevin (Eds.),
Contact Dermatitis 5th Edition
Springer-Verlag, Berlin Heidelberg, Germany (2011), pp. 439-464

J-M. Lachapelle, H. I. Maibach:
"Patch Testing and Prick Testing - A practical Guide
Official Publication of the ICDRG"
Third Edition
Springer-Verlag, Berlin Heidelberg, Germany (2012)

Appendix: test protocol

14.12.2023 **Product: Ecoworks Laundry Alpha**
PROTOCOL formulation code: SCLLD/GC 005/10/23

No.	Type	after 48 h			after 72 h		
		E	F	S	E	F	S
1	S	0	0	0	0	0	0
2	S	0	0	0	0	0	0
3		0	0	0	0	0	0
4	S	0	0	0	0	0	0
5	S	0	0	0	0	0	0
6	E	0	0	0	0	0	0
7	E	0	0	0	0	0	0
8		0	0	0	0	0	0
9		0	0	0	0	0	0
10	S	0	0	0	0	0	0
11	S	0	0	0	0	0	0
12		0	0	0	0	0	0
13		0	0	0	0	0	0
14	S	0	0	0	0	0	0
15		0	0	0	0	0	0
16		0	0	0	0	0	0
17	E	0	0	0	0	0	0
18		0	0	0	0	0	0
19	S	0	0	0	0	0	0
20		0	0	0	0	0	0
21	S	0	0	0	0	0	0
22		0	0	0	0	0	0
23	S	0	0	0	0	0	0
24		0	0	0	0	0	0
25		0	0	0	0	0	0
26		0	0	0	0	0	0
27	S	0	0	0	0	0	0
28	E	0	0	0	0	0	0
29		0	0	0	0	0	0
30		0	0	0	0	0	0
31		0	0	0	0	0	0
32		0	0	0	0	0	0
33	S	0	0	0	0	0	0
34		0	0	0	0	0	0
35		0	0	0	0	0	0
36	S	0	0	0	0	0	0
37		0	0	0	0	0	0
38		0	0	0	0	0	0
39		0	0	0	0	0	0
40		0	0	0	0	0	0
41	E	0	0	0	0	0	0
42		0	0	0	0	0	0
43		0	0	0	0	0	0
44		0	0	0	0	0	0
45	A	0	0	0	0	0	0
46		0	0	0	0	0	0
47		0	0	0	0	0	0
48		0	0	0	0	0	0
49	S	0	0	0	0	0	0
50		0	0	0	0	0	0
SUM		0,0	0,0	0,0	0,0	0,0	0,0

Erythema (E): no E.: 0, slight E.: 1, clear E.: 2, severe E.: 3, very severe E.: 4
Fissures (F): no F.: 0, minimal F.: 1, clearly visible F.: 2, distinct F.: 3, ulceration: 4
Scales (S): no S.: 0, minimal S.: 1, clearly visible S.: 2, moderate S.: 3, distinct S.: 4

S: subjects with sensitive skin
E: patients with eczema
A: patients with allergy

14.12.2023 **Product: SDS (1% in water)**
PROTOCOL

No.	Type	after 48 h			after 72 h		
		E	F	S	E	F	S
1	S	0	0	0	0	0	0
2	S	2	0	0	2	0	0
3		0	0	0	0	0	0
4	S	0	0	0	0	0	0
5	S	1	0	0	1	0	0
6	E	1	0	0	0	0	0
7	E	2	0	2	2	0	1
8		0	0	0	0	0	0
9		0	0	0	0	0	0
10	S	1	0	0	1	0	0
11	S	0	0	0	0	0	0
12		0	0	0	0	0	0
13		0	0	0	0	0	0
14	S	1	0	0	1	0	0
15		0	0	0	0	0	0
16		0	0	0	0	0	0
17	E	1	0	1	1	0	0
18		0	0	0	0	0	0
19	S	0	0	0	0	0	0
20		0	0	0	0	0	0
21	S	0	0	0	0	0	0
22		0	0	0	0	0	0
23	S	0	0	0	0	0	0
24		0	0	0	0	0	0
25		0	0	0	0	0	0
26		0	0	0	0	0	0
27	S	0	0	0	0	0	0
28	E	1	0	1	1	0	1
29		0	0	0	0	0	0
30		1	0	0	1	0	0
31		0	0	0	0	0	0
32		0	0	0	0	0	0
33	S	1	0	0	1	0	0
34		0	0	0	0	0	0
35		0	0	0	0	0	0
36	S	2	0	1	2	0	1
37		0	0	0	0	0	0
38		0	0	0	0	0	0
39		0	0	0	0	0	0
40		0	0	0	0	0	0
41	E	1	0	0	1	0	0
42		0	0	0	0	0	0
43		0	0	0	0	0	0
44		0	0	0	0	0	0
45	A	1	0	0	0	0	0
46		0	0	0	0	0	0
47		0	0	0	0	0	0
48		0	0	0	0	0	0
49	S	1	0	0	1	0	0
50		1	0	1	1	0	1
SUM		0,36	0,0	0,12	0,32	0,0	0,08

Erythema (E): no E.: 0, slight E.: 1, clear E.: 2, severe E.: 3, very severe E.: 4
Fissures (F): no F.: 0, minimal F.: 1, clearly visible F.: 2, distinct F.: 3, ulceration: 4
Scales (S): no S.: 0, minimal S.: 1, clearly visible S.: 2, moderate S.: 3, distinct S.: 4

S: subjects with sensitive skin
E: patients with eczema
A: patients with allergy

14.12.2023 **Product: Water**
PROTOCOL

No.	Type	after 48 h			after 72 h		
		E	F	S	E	F	S
1	S	0	0	0	0	0	0
2	S	0	0	0	0	0	0
3		0	0	0	0	0	0
4	S	0	0	0	0	0	0
5	S	0	0	0	0	0	0
6	E	0	0	0	0	0	0
7	E	0	0	0	0	0	0
8		0	0	0	0	0	0
9		0	0	0	0	0	0
10	S	0	0	0	0	0	0
11	S	0	0	0	0	0	0
12		0	0	0	0	0	0
13		0	0	0	0	0	0
14	S	0	0	0	0	0	0
15		0	0	0	0	0	0
16		0	0	0	0	0	0
17	E	0	0	0	0	0	0
18		0	0	0	0	0	0
19	S	0	0	0	0	0	0
20		0	0	0	0	0	0
21	S	0	0	0	0	0	0
22		0	0	0	0	0	0
23	S	0	0	0	0	0	0
24		0	0	0	0	0	0
25		0	0	0	0	0	0
26		0	0	0	0	0	0
27	S	0	0	0	0	0	0
28	E	0	0	0	0	0	0
29		0	0	0	0	0	0
30		0	0	0	0	0	0
31		0	0	0	0	0	0
32		0	0	0	0	0	0
33	S	0	0	0	0	0	0
34		0	0	0	0	0	0
35		0	0	0	0	0	0
36	S	0	0	0	0	0	0
37		0	0	0	0	0	0
38		0	0	0	0	0	0
39		0	0	0	0	0	0
40		0	0	0	0	0	0
41	E	0	0	0	0	0	0
42		0	0	0	0	0	0
43		0	0	0	0	0	0
44		0	0	0	0	0	0
45	A	0	0	0	0	0	0
46		0	0	0	0	0	0
47		0	0	0	0	0	0
48		0	0	0	0	0	0
49	S	0	0	0	0	0	0
50		0	0	0	0	0	0
SUM		0,0	0,0	0,0	0,0	0,0	0,0

Erythema (E): no E.: 0, slight E.: 1, clear E.: 2, severe E.: 3, very severe E.: 4
Fissures (F): no F.: 0, minimal F.: 1, clearly visible F.: 2, distinct F.: 3, ulceration: 4
Scales (S): no S.: 0, minimal S.: 1, clearly visible S.: 2, moderate S.: 3, distinct S.: 4

S: subjects with sensitive skin
E: patients with eczema
A: patients with allergy

ECOWORKS

ECOWORKS LAUNDRY DETERGENT (ALPHA FORMULATION)

PCR Corp Report

GLOBAL PRODUCT TESTING

SUMMARY REPORT

A MODIFIED DRAIZE REPEAT INSULT PATCH TEST IN A SHARED PANEL OF 53 HEALTHY VOLUNTEERS, TO INVESTIGATE THE IRRITATION AND SENSITISATION POTENTIAL OF ONE (1) TEST ARTICLE FOLLOWING REPEATED CUTANEOUS PATCH APPLICATIONS

CONDUCTED ACCORDING TO PCR MASTER PROTOCOL: PCRRIP1(20JAN2022)

PCR Corp. Study Number: **KRCRIP2M**

TEST ARTICLES 1: Ecoworks Laundry Alpha (SCLLD/GC 005/10/23)

Please Note: PCR Corp is an abbreviation for Princeton Consumer Research Corp.

Prepared by:

PCR Corp
8 Richmond Road
Dukes Park
Chelmsford
Essex
CM2 6UA
United Kingdom

Draft Report: 29th January 2024
Final Report: 27th February 2024

A MODIFIED DRAIZE REPEAT INSULT PATCH TEST IN A SHARED PANEL OF 53 HEALTHY VOLUNTEERS, TO INVESTIGATE THE IRRITATION AND SENSITISATION POTENTIAL OF ONE (1) TEST ARTICLE FOLLOWING REPEATED CUTANEOUS PATCH APPLICATIONS

CONDUCTED ACCORDING TO PCR MASTER PROTOCOL: PCRRIP1(20JAN2022)

PCR Corp. Study Number: **KRCRIP2M**

I declare that the following report constitutes a true and faithful account of the procedures adopted and the results obtained in the performance of this study. The aspects of the study conducted by PCR Corp were performed, where relevant, in accordance with the principles of Good Clinical Research Practice.

Barrie Drewitt
(Principal Investigator)

B Drewitt

Date 28 / 02 / 2024

Charlie Gould
(Project Manager)

C Gould

Date 28 / 02 / 2024

Dr. Geetha Kugan, MRCP, DCH, FRCPCH
(Consulting Paediatrician)

Geetha Kugan

Date 28 / 02 / 2024

QUALITY ASSURANCE STATEMENT

This report has been audited and is considered to be an accurate description of the methods used and an accurate presentation of the data obtained during the conduct of the study.

Bryan Baker
(Quality Assurance)

R. Sherrington

Date 28 / 02 / 2024

TABLE OF CONTENTS

KEY STUDY PERSONNEL AND RESPONSIBILITIES

Key Personnel	General Responsibilities
Principal Investigator (PI) Barrie Drewitt PCR Corp Baypoint Commerce Center 9600 Koger Blvd N St Petersburg FL 33702 USA Tel: +1(727) 576 7300	The Principal Investigator (PI) responsible for ensuring sufficient resources were available to conduct the study and was responsible for the study design, review of the study protocol, authorization and summary report.
Study Supervisor (SS) Andrew King PCR Corp 164A Plymouth Grove Manchester M13 0AF United Kingdom Tel: 44(0)161 791 1797	The Study Supervisor (SS) responsible for the conduct of the study on a daily basis.
Consulting Pediatrician Dr. Geetha Kugan, MRCP, DCH, FRCPCH	The Consulting Paediatrician has reviewed the study results and concurs with the study result conclusions.
Project Manager (PM) Charlie Gould Princeton Consumer Research 8 Richmond Road Dukes Park Chelmsford CM2 6UA United Kingdom Tel: +44(0)1245 934050	The Project Manager (PM) involved with the study authorization, compilation of study results and summary report.

INTRODUCTION AND OBJECTIVE

The objective of this study was to investigate the irritation and sensitisation potential of cosmetic test articles, in a shared panel of 53 healthy volunteers by means of repeated cutaneous occlusive patch applications based on the modified Draize method of Jordan and King (1977)[1] to support claims such as "Dermatologically Tested", "Clinically Tested", "Clinically Proven", "Kind to Skin", "Safe for Skin", "Mild for Skin", Suitable for Eczema prone skin", Paediatrician Approved", and "Suitable for Newborns".

MATERIALS AND METHODS

1. STUDY DESIGN

The study was conducted single blind, at a single center according to Master Protocol: PCRRIP1

The test article was patched under occlusive conditions using Finn chambers or equivalent occlusive patches. A total of nine inductions patches worn for 47 hours or 71 hours (patching occurred Mondays, Wednesdays, and Fridays) for three weeks (a make-up day was allowed to ensure subjects had all 9 induction patches). Subjects had a rest period of 14 days. Challenge patches were applied for 48 hours and readings were made 1 hour and 48 hours post removal.

2. TEST MATERIALS

2.1. Test Articles

The test article was supplied by the Sponsor and labelled as follow:

TA#	Test Article Name/Description	ID Code (Batch/Lot #)	Dilution/special handling*
1	Ecoworks Laundry Alpha	(SCLLD/GC 005/10/23)	Use as supplied

3. STUDY ETHICS

3.1. Declaration of Helsinki

The study conformed to the requirements of the 1964 Declaration of Helsinki and its subsequent amendments (World Medical Association; 2013)[2].

3.2. Indemnity Provision

The Sponsor shall be responsible, without regard to legal liability, and shall indemnify PCR Corp, or any of their respective officers or employees in the event of claims for compensation from subjects suffering injury arising out of the administration or use of the test article, or of any procedure required under this protocol as a result of a subject participating in this study, except and insofar as such claims arise as a result of any negligent act or omission on the part of PCR Corp employees or any persons undertaking or involved in the study by arrangement with PCR Corp.

3.3. ICH GCP

The study was conducted in accordance with applicable International Council for Harmonization. 2016. Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2)[3] in as much as they apply to cosmetic and consumer product testing/research.

4. QUALITY ASSURANCE

The study was conducted according to the Sponsor Authorization, the master protocol, the Standard Operating Procedures of PCR Corp and according to the applicable ICH Guidelines on Good Clinical Practice, and other recognised guidelines. An audit of the final report was completed, for accuracy and completeness of presentation. Additionally, the study may be subject to the following Quality Assurance procedures:

- Review of protocol and protocol amendments for completeness, clarity and adequacy.
- Inspection and/or audit of critical phases of study conduct for compliance with protocol and PCR Corp procedures.

PCR Corp Quality Assurance would have informed PCR Corp management of any findings that may have affected the integrity of the study.

5. RETENTION OF DATA

All raw data generated by PCR Corp during the course of the study, including the sponsor authorization form and final summary report, will be retained in the PCR Corp Archive for a minimum period of three years from study completion as is PCR Corp policy for cosmetic products. In the event of original data being transferred to the Sponsor at their request, exact copies will be so retained. At no time will archived data be destroyed without prior written approval of the Sponsor. All study data will be available at any time, by appointment, for inspection by the Sponsor or their authorized representative. The study master protocol will be archived and retained indefinitely at PCR Corp.

6. REFERENCES

1. Jordan W.P. and King S. E. (1977) Contact Dermatitis 3, 19-26.

2. World Medical Association (2013). "Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects". JAMA 310 (20): 2191–2194. doi:10.1001/jama.2013.281053

3. ICH E6_R2, INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE, Current Step 4 version dated 9 November 2016

RESULTS

1 Location and Dates of the Study

The study was performed at PCR Corp, located in Manchester between w/c 4th December 2023 and w/e 15th January 2024.

2 Subjects

56 male and female subjects were enrolled into the study. 53 subjects completed the study. The age & gender of these subjects is presented in table in Appendix 2.

3 Adverse events, Adverse Reactions and Subjects Not Completing the Study, Deviations

No adverse events or reactions were reported.

3 subjects withdrew for personal reasons.

There were no deviations that occurred during the conduct of the study.

4 Assessments

Individual reactions to the test article is presented in Appendix 1.

As demonstrated by the individual skin responses to the test article:

Test Article 1 – Ecoworks Laundry Alpha (SCLLD/GC 005/10/23) elicited barely visible erythematous reactions during the induction phase of the study.

There were no questionable reactions observed during the Challenge Phase (Days 38 and 40) by any of the subjects to the test article. These results support the assessment that under the conditions of the study, the test article has demonstrated a low potential for irritation and sensitization.

CONCLUSIONS

The test article can be considered as safe for use under the conditions of the study, and claims such as, "Dermatologically Tested", "Clinically Tested", "Clinically Proven", "Kind to Skin", "Safe for Skin", "Mild for Skin", Suitable for Eczema prone skin", Pediatrician Approved", and "Suitable for Newborns".

APPENDIX 1: INDIVIDUAL RESPONSES

TEST ARTICLE 1 – Ecoworks Laundry Alpha (SCLLD/GC 005/10/23)

Number	Code	2	3	4	5	6	7	8	9	10	AU	1 hour	47 hour
1	1	0	0	0	0	0	0	0	0	0		0	0
2	1	0	0	0	0	0	0 A	0 A	0 A	0 A		0	0
3	1	0	0	0	0	0	0	0	0	0		0	0
4	1	0	0	0	0	0	0	0	0	0		0	0
5	1	0	0	0	0	0	0	0	0	0		0	0
6	1	0	0	0	0	0	0	0	0	0		0	0
7	1	0	0	0	0	0	0 A	0 A	0 A	0 A		0	0
8	1	0	0	0	0	0	0	0	0	0		0	0
9	1	0	0	0	0	0	0	0	0	0		0	0
10	1	0	0	0	0	0	0	0	0	0		0	0
11	1	0	0	0	0	0	0	0	0	0		0	0
12	1	0	0	0 A	0 A	0 A	1 A	1 A	1 A	1 A		0	0
13	1	0	0	0	0	0	0	0	0	0		0	0
14	1	0	–	0	0	0	0	0	0	0	0	0	0
15	1	0	0	0	0	0	0	0	0	0		0	0
16	1	0	0	0	0	0	0	0	0	0		0	0
17	1	0	0	0	0	0 A	–	0 A	0 A	0 A	0 A	0	0
18	1	0	0	0	0	0	0	0	0	0		0	0
19	1	0	0	0	0	0	0	0	0	0		0	0
20	1	0	0	0	0 A	0 A	0 A	0 A	0 A	0 A		0	0
21	1	0	0	0	0	0	0	0	0	0		0	0
22	1	0	0	0	0	0	0	0	0	0		0	0
23	1	0	0	0	0	0	0 A	0 A	1 A	1 A		0	0
24	1	0	0	0	0	0	0	0	0	0		0	0
25	1	0	0	0	0	0	0	0	0	0		0	0
26	1	0	0	0	0	0	0	0	0	0		0	0
27	1	0	0	–	B/O	B/O	B/O	B/O	B/O	B/O		B/O	B/O
28	1	0	0	0	0	0	0	0	0	0		0	0
29	1	0	0	0	0	0	0	0	0	0		0	0
30	1	0	0	0	–	0	0	0	0	0	0	0	0
31	1	0	0	0	–	0	B/O	B/O	B/O	B/O		B/O	B/O
32	1	0	0	0	0	0	0	0	0	0		0	0
33	1	0	0	0	0	0	0	0	0	0		0	0
34	1	0	0	0	0	0	0	0	0	0		0	0
35	1	0	0	0	0	0	0	0	0	0		0	0
36	1	0	0	0	0	0	0	0 A	0 A	0 A		0	0
37	1	0	0	–	0	0	0	0	0	0	0	0	0
38	1	0	0	0	0	0	0	0	0	0		0	0
39	1	0	0	0	0	0	0 A	0 A	0 A	0 A		0	0
40	1	0	0	0	0	0	0	0	0	0		0	0
41	1	0	0	0	0	0	0	0	0	0		0	0
42	1	0	0	0	0	0	0 A	1 A	1 A	1 A		0	0
43	1	0	0	0	0	0	0	0	0	0		0	0
44	1	0	0	0	0	0	0	0	0	0		0	0
45	1	0	0	0	0	0	0	0	0	0		0	0
46	1	0	0	0	0	0	0	0	0	0		0	0
47	1	0	0	0	0	0	0	0	0	0		0	0
48	1	0	0	0	0	0 A	0 A	0 A	0 A	0 A		0	0
49	1	0	0	0	0	0	0	0	0	0		0	0
50	1	0	0	0	0	0	0	0	0	0		0	0
51	1	0	–	B/O	B/O	B/O	B/O	B/O	B/O	B/O		B/O	B/O
52	1	0	0	0	0	0	0	0	0	0		0	0
53	1	0	0	0	0	0	0	0	0	0		0	0
54	1	0	0	0	0	0	0	0	0	0		0	0
55	1	0	0	0	0 A	0 A	0 A	0 A	0 A	0 A		0	0
56	1	0	0	0	0	0	0	0	0	0		0	0
MEAN		0.00	0.00	0.00	0.00	0.00	0.02	0.04	0.06	0.06	0.00	0.00	0.00
STDEV		0.00	0.00	0.00	0.00	0.00	0.14	0.19	0.23	0.23	0.00	0.00	0.00

APPENDIX 2: SUBJECT DEMOGRAPHICS

SUBJECT NUMBER	MALE OR FEMALE	AGE	SKIN TYPE
1	Female	27	Eczema
2	Female	40	Eczema
3	Female	18	Normal
4	Female	22	Eczema
5	Male	34	Normal
6	Female	36	Normal
7	Female	20	Eczema
8	Male	19	Eczema
9	Female	20	Normal
10	Male	21	Eczema
11	Male	34	Normal
12	Female	26	Normal
13	Female	37	Eczema
14	Female	25	Eczema
15	Female	18	Normal
16	Female	37	Eczema
17	Male	24	Eczema
18	Female	26	Normal
19	Female	27	Normal
20	Male	18	Normal
21	Male	29	Eczema
22	Male	40	Eczema
23	Female	42	Normal
24	Male	20	Eczema
25	Female	26	Normal
26	Male	40	Eczema
27	Male	22	Normal
28	Female	21	Eczema
29	Male	19	Normal
30	Female	28	Eczema
31	Female	37	Eczema
32	Female	43	Normal
33	Female	19	Eczema
34	Female	22	Normal
35	Male	46	Eczema
36	Female	33	Normal
37	Female	28	Normal
38	Male	27	Eczema
39	Female	29	Eczema
40	Male	23	Normal
41	Male	29	Eczema
42	Female	62	Eczema
43	Female	59	Normal
44	Female	26	Eczema
45	Female	32	Normal
46	Female	24	Normal
47	Male	52	Eczema
48	Female	48	Eczema
49	Female	45	Normal
50	Male	40	Eczema
51	Female	49	Normal
52	Male	49	Eczema
53	Female	27	Normal
54	Female	35	Eczema
55	Male	42	Normal
56	Female	28	Normal

APPENDIX 3: INCI LISTINGS

Test Article 1: Ecoworks Laundry Alpha (SCLLD/GC 005/10/23)

Product Name: Ecoworks Laundry Alpha
Code: SCLLD/GC 005/10/23